Fig. 3

Combination of PI3K and EGFR inhibitors markedly suppresses PTEN-deficient and EGFR-overexpressing BLBC tumor growth in vivo. a Mice with established MDA-MB-468 xenograft tumors were treated with PWT-458 (100 mg/kg 5 times/week), gefitinib (150 mg/kg five times/week), combination of both drugs, or vehicle control, and tumor size was measured by caliper two times per week. The results are presented as the mean tumor volume ± S.E.M. (n = 5 mice/group). b Representative tumors from mice in (a) were lysed 5 h after the final treatment with the indicated drugs. Tumor lysates were subjected to Western blot analysis for the indicated proteins